fda warning letters glp-1 october 2025 news Issues Warnings Against Illegal Marketing FDA issued 30 warning letters

Do not stop abruptly without medical guidance

Meals become smaller naturally

Those with established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in outcome trials

The FDA previously allowed compounded tirzepatide to be made due to a national shortage, but that shortage has been resolved, and pharmacies and outsourcing facilities are no longer allowed to compound, distribute, or dispense compounded GLP-1 medications, including tirzepatide

Our team at TrimrX can help you navigate the complexities of insurance verification to understand your benefits

For diabetes management, dose adjustments are guided by glycemic control markers, primarily HbA1c and self-monitored blood glucose readings